Figure 1 (Rethymic 01)
Rethymic Implant
Product Images NDC 72359-001
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rethymic (NDC 72359-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sumitomo Pharma America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Rethymic 02)
Figure 3 (Rethymic 03)
Figure 4 (Rethymic 04)
Figure 5 (Rethymic 05)
This appears to be a table and information related to clinical trials and survival estimate for a RETHYMIC trial population consisting of 95 patients and a natural history population consisting of 49 patients. The table contains information on the number of patients and the survival rate over time. The patients in the RETHYMIC trial population were censored at the time of their recent follow-up, however, no patients in the natural history population were censored. The time is measured in years after the administration for the RETHYMIC clinical trial population and years of life for the natural history population.*
Principal Display Panel (11 Container Box)
This is a description for a medical product with the National Drug Code (NDC) 7235900101. The product is made of processed thymus tissue called RETHYMIC, which has a dosage of 5000-22,000 mm² per recipient body surface area. The entire lot of the product contains 22,000 mm-2 RETHYMIC and is formulated in media supplemented with fetal bovine serum and is preservative-free. Users should handle the product aseptically, not agitate or sterilize it, store it at room temperature, and not freeze or refrigerate it. The product's Lot number is GMP- 336, and its expiration date is August 17, 2021. The product is manufactured for Enzyvant Therapeutics Inc located in Cambridge, MA, and their telephone number is 1-833369-9868.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
